GlassScriptPhysician profile
Deborah S Johnson
NPI 1558750950
$9,843.68
in general payments reported to CMS, 2019-2025
45 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,945 · 2022: $2,224 · 2023: $2,414 · 2024: $1,732 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,578 · Education: $96.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,578.39 |
| Education | $96.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,649.78 | 2021-2025 | |
| Novo Nordisk INC | $1,422.36 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,024.62 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $832.49 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $735.23 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Astrazeneca Pharmaceuticals LP | $548.98 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $328.79 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $314.43 | 2021-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Astellas Pharma US INC | $229.11 | 2021-2023 | Myrbetriq, Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $219.85 | 2022 | |
| Sumitomo Pharma America, INC. | $211.10 | 2023-2024 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $191.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $181.17 | 2021-2023 | Trintellix |
| Dexcom, INC. | $150.10 | 2023-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $145.22 | 2022-2025 | Caplyta |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.83 | 2021-2023 | |
| Axsome Therapeutics, INC. | $136.80 | 2024-2025 | Auvelity, Symbravo |
| Glaxosmithkline, LLC. | $127.06 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Nestle Healthcare Nutrition INC. | $123.86 | 2021-2023 | |
| Lundbeck LLC | $106.85 | 2022-2025 | Rexulti |
| Forte Bio-Pharma LLC | $71.54 | 2023-2024 | Prolate, Nalocet |
| Novartis Pharmaceuticals Corporation | $68.25 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.71 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $64.33 | 2021-2023 | Xarelto |
| Neurocrine Biosciences, INC. | $62.05 | 2024 | Ingrezza |
| Mylan Specialty L.P. | $61.82 | 2021-2023 | Yupelri |
| Corium, LLC | $61.76 | 2023-2025 | Azstarys |
| Ironwood Pharmaceuticals, INC | $59.79 | 2021-2024 | Linzess |
| Amgen INC. | $55.21 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $48.80 | 2024-2025 | Voquezna |
| Globus Medical, INC. | $47.17 | 2025 | Senza |
| Sanofi-Aventis U.S. LLC | $47.06 | 2023 | |
| Xeris Pharmaceuticals, INC. | $39.39 | 2023 | Gvoke Hypopen |
| Viatris Specialty LLC | $38.89 | 2025 | Yupelri |
| Vanda Pharmaceuticals INC. | $32.16 | 2025 | Fanapt |
| Boston Scientific Corporation | $31.99 | 2022 | |
| Idorsia Pharmaceuticals US INC | $27.01 | 2023 | Quviviq |
| Organon LLC | $26.79 | 2021-2023 | Nexplanon |
| Abbott Laboratories | $23.77 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.18 | 2024 | Xtampza |
| Ardelyx, INC. | $17.20 | 2025 | Ibsrela |
| Verona Pharma, INC. | $14.00 | 2025 | Ohtuvayre |
| Eisai INC. | $13.21 | 2021 | |
| Tris Pharma INC | $12.00 | 2022 | |
| Genentech USA, INC. | $10.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.